Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Wall Street To Follow Europe And China Gains

Fri, 10th Jul 2015 11:07

LONDON (Alliance News) - UK shares are higher Friday midday as Wall Street is expected to take a positive lead from European stocks, boosted by optimism for a deal between Greece and its creditors, and another positive session for Chinese stock markets.

The FTSE 100 index is up 1.3% at 6,667.00, with only three stocks in the red. The FTSE 250 is up 0.9% at 17,448.15, and the AIM All-Share is up 0.4% at 747.45.

European stocks are once again outperforming London, with the CAC 40 in Paris up 2.9% and the DAX 30 in Frankfurt up 2.1%.

Meanwhile, US futures point to a higher open, with the Dow Jones Industrial Average pointed up 1.0%, the S&P 500 up 1.1% and the Nasdaq 100 up 1.2%.

The most important event in the US will be later in the afternoon, as US Federal Reserve Chair Janet Yellen is due to speak about the economic outlook in Cleveland, Ohio, at 1730 BST. Before that, US wholesale inventories are expected 1500 BST.

"With tensions high over the possible approval of a Greek bailout over the weekend, Yellen will probably try not to signal any change to her economic outlook," says CMC Markets analyst Jasper Lawler. "She will receive questions though, so there is some scope for something unexpected."

Outside the US, attention is on Greece. In a move seen as the Mediterranean country's final bid to keep the euro, the government placed a cash-for-reforms proposal before creditors late Thursday. It comprises spending cuts and tax hikes in exchange for a third bailout, acceptance of which will pave the way for further negotiations between both sides.

Eurogroup President Jeroen Dijsselbloem received the proposal from Greece, his spokesman Michel Reijns said in a Twitter message. Eurozone finance ministers will meet on Saturday in Brussels to review the Greek request.

That was meant to be followed by a summit attended by 28 national leaders of the EU on Sunday to reach a final agreement. However an EU official said Friday morning that no EU summit will be held on Sunday if the Eurogroup of finance ministers agrees with the Greek offer on Saturday.

Prime Minister Alexis Tsipras' request for at least EUR53.5 billion in bailout funds for the next three years will be presented in the Greek parliament for approval on Friday. The new list of reforms makes concessions to creditors' demands in key areas including VAT and pension reform, according to a copy of the document seen by dpa.

The Greek program is "serious, credible" and shows "a determination to remain in the euro area", French President Francois Hollande said in a message on Twitter. Nothing is decided yet, everything can be done, he added.

However, IG Markets analyst Alastair McCaig says "there still remains the tricky issue of the Greek parliament approving this proposal, which was by and large rejected in a national referendum less than a week ago," he writes. "Assuming that the Greeks can all agree with themselves we would then need to see the creditors approve this proposal over the weekend. Of course the more cynical market observer will be asking themselves how reliable a Greek promise is anyway."

London and European stocks also are being supported by a second consecutive session of strong gains by Chinese stock markets following successive declines. The Hang Seng closed up 2.1% in Hong Kong and the Shanghai Composite rose 4.5%.

The gains came as China's securities regulator banned senior management and investors who own stakes in businesses exceeding 5% from selling their shares for next six months, and China's central bank injected CNY35 billion into the money market by buying bonds.

The recovery in Chinese equities also lifted metal prices, after they had fallen to multi-year lows earlier in the week.

"This quick recovery [in metal prices] supports our view of fundamentals having taken a backseat as markets were predominantly driven by concerns about Chinese growth and uncertainties related to the equity market correction," says Carsten Menke, commodities research analyst at Julius Baer.

"It remains to be seen whether the Chinese economy will escape unscathed from the equity market correction or whether it will weigh on consumption, e.g. purchases of jewellery and cars," the analyst adds.

The recovery has supported shares in London-listed miners, with BHP Billiton up 2.0%, Glencore up 1.2% and Anglo American up 1.0%.

Elsewhere on the corporate front, InterContinental Hotels Group is up 3.0% after it has agreed to sell its stake in the InterContinental Hong Kong to Supreme Key for USD938 million. Nomura says the value is at the top end of the broker's appraised value of USD783-940 million, and Numis says this looks like a "very acceptable price" and the achieved price is some USD150 million above its expectation.

IHG will retain a 37-year management contract for the hotel, with three ten-year extension rights. It expects to be paid management fees of around USD8 million a year, which will increase after the refurbishment is completed.

International Consolidated Airlines Group is up 2.6%, after Irish budget carrier Ryanair Holdings said its board has voted unanimously to accept IAG's offer for its stake in Aer Lingus Group, removing the final barrier in the way of IAG's takeover bid and paving the way for the protracted transaction to go through. Ryanair shares trade up 2.7%, and Aer Lingus is up 2.4%.

In the AIM All-Share, Aurasian Minerals shares are up 18%. The South-East Asian focused miner said it has appointed Peter Mullens as its new chief executive, and that Mullens has agreed to subscribe to new Aurasian shares alongside a new non-executive director to raise GBP207,500 for the company. The company said Mullens has over 30 years of experience in mining and exploration geology and is currently a director of Royal Road Minerals, which is listed on the Toronto Stock Exchange. Previously, he had held roles at Lydian International and Aquiline Resources.

Reneuron Group is up 16% at 5.66p. The stem-cell company posted a widened pretax loss for its 2015 financial year due to rises in research and development and administrative costs, but said it has placed 1.37 billion shares at 5 pence per share to raise GBP68.4 million to back its therapeutic programmes. Shares in the company closed at 4.875 pence on Thursday.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
11 Mar 2013 08:31

ReNeuron Group wins grants for stem cell therapy development

ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy. The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council. The first award of £0.4m will be used for

Read more
29 Jan 2013 10:29

ReNeuron Group edges further in stem cell therapy research for stroke patients

ReNeuron Group received the green light to complete the final stages of first phase safety testing of its ReN001 stem cell therapy for disabled stroke patients in Scotland, the company announced Tuesday. The ReN001 stem cell therapy was being administered in ascending doses to a total of 12 stroke

Read more
5 Nov 2012 08:33

Angel Biotech signs new contract with ReNeuron

Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year. The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients. ReNeuron's ReN001

Read more
17 Oct 2012 07:27

ReNeuron progresses stroke clinical trial

ReNeuron has reported further progress in the clinical trial of its ReN001 stem cell therapy for disabled stroke patients, known as the PISCES study. The third and penultimate batch of three patients have all been successfully treated with ReN001 and discharged from hospital with no acute safety is

Read more
11 Sep 2012 14:25

Small caps round-up: ReNeuron, Havelock, Goodwin

Clinical-stage stem cell group ReNeuron has achieved further significant milestones with its ReN001 and ReN009 programmes in stroke and critical limb ischaemia, with the filing of two further clinical trial applications to progress the clinical development of these novel therapies. Michael Hunt, Chi

Read more
14 Aug 2012 12:35

Small caps round-up: ReNeuron, Eckoh, Healthcare Locums

Clinical-stage stem cell group ReNeuron surged on Tuesday after saying that the Data Safety Monitoring Board gave a favourable recommendation to proceed to the with a higher dose of its ReN001 stem cell therapy in a clinical trial. 'This represents a further important milestone for the study as we m

Read more
28 Jun 2012 14:22

ReNeuron's full-year results disappoint

ReNeuron Group, a UK-based stem cell company, suffered a decline in its share price on Thursday after posting an increase in pre-tax losses for the year ended March 31st. Loss before tax widened from £6.64m to £6.8m year-on-year (y/y), while revenues rose from £0.029m to £0.04m, representing royal

Read more
16 May 2012 15:18

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and impleme

Read more
27 Apr 2012 14:20

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Read more
3 Apr 2012 12:39

Small caps round-up: DQ Entertainment, Tristel, ReNeuron

DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the seco

Read more
11 Jan 2012 10:55

ReNeuron down despite positive data release

In its second announcement of the year, ReNeuron, the Surrey based stem cell developer, has announced new data on the stability of the company's CTX stem cell line. Researchers from University College London are due to tell a conference in San Diego that the results show "CTX cells retained their m

Read more
3 Jan 2012 08:19

ReNeuron announces positive data

Stem cells therapy developer ReNeuron has gained positive data from a recent pre-clinical study which used its ReN001 stem cell therapy for disabled stroke patients. The newly-published data show significantly improved outcomes in the key behavioural tests in the cell-treated group. A gradual im

Read more
13 Sep 2011 15:09

ReNeuron successfully treats first patient

Stem cells therapy developer ReNeuron has successfully treated a stroke patient who underwent the safe, first-time administration of a higher dose of its new drug, ReN001. The firm ran the increased level of the stem cell therapy drug after the independent Data Safety Monitoring Board recommended t

Read more
13 Dec 2010 18:06

ReNeuron cash call will last two years

Stem cell therapies developer ReNeuron is raising £10m from a share issue at 5.5p a share. The cash will finance the pre-clinical and clinical development costs of the main drug programmes, as well as general running costs, for the next two years. The cash will also be used to complete manufacturi

Read more
12 Jul 2010 08:31

Small caps round-up: Ariana Resources, Michelmersh, ReNeuron...

Shares in Ariana Resources rallied after the Turkey-focused gold miner announces the completion of its joint venture agreement with Proccea to develop the Red Rabbit Project in western Turkey. The group said results from the recent resource drilling programme are expected shortly. Managing directo

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.